. 2020 Jan 14;10(7):1253–1278. doi: 10.1016/j.apsb.2020.01.003
© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 21.
Pyrrolidone-based MDM2 inhibitors.